378 Chapter 12 331. Vernet C, Arnulf I. Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. Sleep. 2009;32(6):753-9. 332. Bassetti C, Gugger M, Bischof M, Mathis J, Sturzenegger C, Werth E, et al. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med. 2003;4(1):7-12. 333. Billiard M, Sonka K. Idiopathic hypersomnia. Sleep Med Rev. 2016;29:23-33. 334. Billiard M, Dauvilliers Y. Idiopathic Hypersomnia. Sleep Med Rev. 2001;5(5):349-58. 335. Nevsimalova S, Susta M, Prihodova I, Horvat EM, Milata M, Sonka K. Idiopathic hypersomnia: a homogeneous or heterogeneous disease? Sleep Med. 2021;80:8691. 336. Bastuji H, Perrin F, Garcia-Larrea L. Event-related potentials during forced awakening: a tool for the study of acute sleep inertia. J Sleep Res. 2003;12(3):189206. 337. Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: A study of 77 cases. Sleep. 2007;30(10):1274-81. 338. Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res. 2010;19(4):525-34. 339. Evangelista E, Rassu AL, Barateau L, Lopez R, Chenini S, Jaussent I, Dauvilliers Y. Characteristics associated with hypersomnia and excessive daytime sleepiness identified by extended polysomnography recording. Sleep. 2021;44(5). 340. Dietmann A, Gallino C, Wenz E, Mathis J, Bassetti CLA. Multiple sleep latency test and polysomnography in patients with central disorders of hypersomnolence. Sleep Med. 2021;79:6-10. 341. Dauvilliers Y, Evangelista E, Barateau L, Lopez R, Chenini S, Delbos C, et al. Measurement of symptoms in idiopathic hypersomnia: The Idiopathic Hypersomnia Severity Scale. Neurology. 2019;92(15):e1754-e62. 342. Won C, Mahmoudi M, Qin L, Purvis T, Mathur A, Mohsenin V. The impact of gender on timeliness of narcolepsy diagnosis. J Clin Sleep Med. 2014;10(1):89-95. 343. Pavoine S, Vallet J, Dufour AB, Gachet S, Daniel H. On the challenge of treating various types of variables: application for improving the measurement of functional diversity. Oikos. 2009;118(3):391-402. 344. Halkidi M, Batistakis Y, Vazirgiannis M. On clustering validation techniques. J Intell Inf Syst. 2001;17(2-3):107-45. 345. Rousseeuw PJ. Silhouettes - a Graphical Aid to the Interpretation and Validation of Cluster-Analysis. J Comput Appl Math. 1987;20:53-65. 346. Moore DS, Notz WI, Flinger MA. The Basic Practice of Statistics. 6 ed: W.H. Freeman and Company; 2013. 347. McGregor R, Thannickal TC, Siegel JM. Pleasure, addiction, and hypocretin (orexin). Handb Clin Neurol. 2021;180:359-74. 348. Del Cid-Pellitero E, Garzon M. Hypocretin1/orexinA-immunoreactive axons form few synaptic contacts on rat ventral tegmental area neurons that project to the medial prefrontal cortex. BMC Neurosci. 2014;15:105. 349. Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, et al. Orexin/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol. 2015;172(2):334-48. 350. Bayard S, Dauvilliers YA. Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy. Front Behav Neurosci. 2013;7:50. 351. Barateau L, Jaussent I, Lopez R, Boutrel B, Leu-Semenescu S, Arnulf I, Dauvilliers Y. Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. Sleep. 2016;39(3):573-80.
RkJQdWJsaXNoZXIy MjY0ODMw